北陆药业(300016) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥207,506,078.84, representing a year-on-year increase of 10.35% compared to ¥188,036,687.69 in the same period last year[3] - The net profit attributable to shareholders decreased by 8.35% to ¥11,526,165.00 from ¥12,576,111.47 in the previous year, while the net profit excluding non-recurring gains and losses increased by 32.95% to ¥11,446,351.32[3] - Operating profit for Q1 2024 reached CNY 15,862,651.22, up 54.5% from CNY 10,281,712.65 in Q1 2023[27] - Net profit for Q1 2024 was CNY 11,621,240.12, representing a 14.1% increase from CNY 10,184,088.91 in the previous year[29] - The company reported a total comprehensive income of CNY 11,621,240.12 for Q1 2024, compared to CNY 10,184,088.91 in the previous year, reflecting a growth of 14.1%[29] Cash Flow - The net cash flow from operating activities was ¥35,344,060.75, a slight decrease of 1.40% from ¥35,846,735.41 in the previous year[3] - The company reported a net cash flow from operating activities of CNY 35,344,060.75, slightly down from CNY 35,846,735.41 in Q1 2023[32] - The net cash flow from investing activities was negative at -¥288,782,400.00, a decrease of 40.37% year-on-year, mainly due to increased cash payments for financial products and equity acquisition intentions[11] - Net cash flow from investment activities was -$288,782,387.03, compared to -$205,732,699.81 previously[34] - Cash inflow from financing activities amounted to $84,000,000.00, up from$69,800,000.00 in the prior period[34] - Cash outflow from financing activities was $47,308,364.84, significantly higher than$8,201,162.06 previously[34] - Net cash flow from financing activities was $36,691,635.16, a decrease from$61,598,837.94 in the previous period[34] - The net increase in cash and cash equivalents was -$216,530,309.24, compared to -$108,716,024.53 previously[34] - The ending balance of cash and cash equivalents was $515,204,730.85, down from$628,227,882.71 in the prior period[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,869,853,260.93, reflecting a 1.79% increase from ¥2,819,424,047.96 at the end of the previous year[5] - The company's total assets amounted to approximately CNY 2.87 billion, an increase from CNY 2.82 billion at the beginning of the period, reflecting a growth of about 1.5%[21] - The company's total liabilities increased from CNY 1.12 billion to CNY 1.14 billion, indicating a rise of approximately 1.8%[21] - Total liabilities increased to CNY 1,070,552,237.60, compared to CNY 1,033,111,812.55 in the previous year, reflecting a growth of 3.6%[26] - The company’s total current liabilities increased from CNY 175.56 million to CNY 192.06 million, an increase of approximately 9.4%[21] - The company’s short-term borrowings rose from CNY 175.56 million to CNY 192.06 million, reflecting an increase of about 9.4%[21] Equity and Investments - The company's total equity reached CNY 1,799,301,023.33, an increase from CNY 1,786,312,235.41, marking a growth of 0.7%[26] - The company’s long-term equity investments slightly decreased from CNY 200.92 million to CNY 197.03 million, a decline of about 1.4%[24] - Long-term borrowings rose to CNY 152,550,000.00, up from CNY 129,950,000.00, indicating a 17.3% increase year-over-year[26] - The company has made a payment of ¥20,000,000.00 for the equity acquisition intention of an 80% stake in Chengde Tianyuan Pharmaceutical Co., Ltd., indicating ongoing market expansion efforts[10] - The company completed the acquisition of 80% equity in Chengde Tianyuan Pharmaceutical Co., Ltd., as approved by the board on April 16, 2024[18] Inventory and Receivables - Accounts receivable decreased from CNY 185.04 million to CNY 166.81 million, a reduction of about 9.8%[21] - The company reported an increase in inventory from CNY 244.86 million to CNY 251.76 million, which is an increase of approximately 2.8%[21] - The company reported a significant increase in prepaid accounts, which rose by 195.94% to ¥21,328,900.00, primarily due to advance payments for raw material purchases[10] Research and Development - Research and development expenses for Q1 2024 were CNY 13,889,933.57, a decrease of 18.8% from CNY 17,042,221.17 in the same quarter last year[27] Other Information - The weighted average return on equity was 0.70%, slightly down from 0.71% in the previous year[3] - The basic earnings per share for Q1 2024 was CNY 0.0235, down from CNY 0.0256 in Q1 2023[29] - The company has not audited the first quarter report[36]